^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YL-17231

    i
    Company:
    Shanghai YingLi Pharma
    Drug class:
    KRAS G12C inhibitor, KRAS G12D inhibitor, pan-KRAS inhibitor
    Related drugs:
    Apply
    Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS (NCT06096974)
    Phase 1
    Shanghai YingLi Pharmaceutical Co. Ltd.
    Not yet recruiting
    Last update posted :
    10/24/2023
    Initiation :
    10/01/2023
    Primary completion :
    04/01/2025
    Completion :
    04/01/2026
    PD-L1 • KRAS • NRAS • HRAS
    |
    KRAS mutation • NRAS mutation • HRAS mutation
    |
    YL-17231
    A Study of YL-17231 in Patients With Advanced Solid Tumors (NCT06078800)
    Phase 1
    Shanghai YingLi Pharmaceutical Co. Ltd.
    Recruiting
    Last update posted :
    10/12/2023
    Initiation :
    09/28/2023
    Primary completion :
    03/01/2025
    Completion :
    12/01/2025
    PD-L1 • KRAS • MSI
    |
    MSI-H/dMMR • KRAS wild-type • RAS wild-type
    |
    YL-17231